News

Yahoo Finance1mon
ENHERTU® Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine ...
Based on DESTINY-Breast06 phase 3 trial results which showed ENHERTU demonstrated superiority versus chemotherapy with a median progression-free survival of more than one year Approval brings ...
Business Insider1y
AstraZeneca: Enhertu Improved PFS In HR-positive, HER2-low Metastatic Breast Cancer
(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) announced Monday that DESTINY-Breast06 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated statistically ...
Reuters1y
Astra's Enhertu breast cancer trial shows 'unprecedented' results
June 2 (Reuters) - AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab Enhertu slows the progression of breast cancer by about five months in women whose disease ...